المؤلفون: Roof L, Geiger JL

المصدر: Cancer Management and Research, Vol Volume 15, Pp 343-350 (2023)

مصطلحات موضوعية: thyroid cancer, differentiated thyroid cancer, targeted therapy, cabozantinib, patient outcomes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/clinical-utility-of-cabozantinib-in-the-treatment-of-locally-advanced--peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/72e0a48af4aa435ea543b7ff36ebb527

المؤلفون: Stabile, LP, Egloff, AM, Gibson, MK, Gooding, WE, Ohr, J, Zhou, P, Rothenberger, NJ, Wang, L, Geiger, JL, Flaherty, JT, Grandis, JR, Bauman, JE

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Cancer, Dental/Oral and Craniofacial Disease, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cetuximab, Dasatinib, Drug Resistance, Neoplasm, Female, Head and Neck Neoplasms, Humans, Interleukin-6, Male, Middle Aged, Squamous Cell Carcinoma of Head and Neck, Survival Analysis, HNSCC, EGFR, Src-family kinases, Dentistry, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/1g89s36c

المؤلفون: Geiger, JL, Bauman, JE, Gibson, MK, Gooding, WE, Varadarajan, P, Kotsakis, A, Martin, D, Gutkind, JS, Hedberg, ML, Grandis, JR, Argiris, A

المصدر: Head & neck, vol 38, iss 12
Geiger, JL; Bauman, JE; Gibson, MK; Gooding, WE; Varadarajan, P; Kotsakis, A; et al.(2016). Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38(12), 1759-1764. doi: 10.1002/hed.24501. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3kk8797t

مصطلحات موضوعية: Male, Maximum Tolerated Dose, Clinical Sciences, and over, Kaplan-Meier Estimate, head and neck squamous cell carcinoma, Risk Assessment, Disease-Free Survival, Drug Administration Schedule, mammalian target of rapamycin (mTOR) inhibitors, head and neck squamous cell carcinoma (HNSCC), Dose-Response Relationship, Rare Diseases, Clinical Research, 80 and over, Humans, Neoplasm Invasiveness, Everolimus, Dental/Oral and Craniofacial Disease, Neoplasm Staging, Aged, Cancer, Carcinoma, clinical trial, Middle Aged, Prognosis, Survival Analysis, Neoplasm Recurrence, Treatment Outcome, Squamous Cell, Local, Otorhinolaryngology, Head and Neck Neoplasms, Dentistry, Female, PIK3CA mutations, Drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::066832df5ae1a9f8afd877ffb41c435b
https://escholarship.org/uc/item/3kk8797t

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Gainor JF; Massachusetts General Hospital, Boston, MA, United States., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, United States., Weber JS; NYU Langone Medical Center, New York, NY, United States., Gutierrez M; Hackensack University Medical Center, Hackensack, NJ, United States., Bauman JE; George Washington University, Washington, DC, United States., Clarke JM; Duke Medical Center, Durham, NC, United States., Julian R; University of Arizona Cancer Center, Tucson, AZ, United States., Scott AJ; Banner University of Arizona Cancer Center, Tucson, AZ, United States., Geiger JL; Cleveland Clinic, Cleveland, PH, United States., Kirtane K; Moffitt Cancer Center, Tampa, Florida, United States., Robert-Tissot C; Moderna, Inc., Cambridge, MA, United States., Coder B; Moderna, Inc., Cambridge, MA, United States., Tasneem M; Moderna, Inc., Cambridge, MA, United States., Sun J; Moderna, Inc., Cambridge, MA, United States., Zheng W; Moderna, Inc., Cambridge, MA, United States., Gerbereux L; Moderna, Inc., Cambridge, MA, United States., Laino A; Moderna, Inc., Cambridge, MA, United States., Porichis F; Moderna, Inc., Cambridge, MA, United States., Russella Pollard J; HiFiBiO Therapeutics, Cambridge, MA, United States., Hou P; Moderna, Inc., Cambridge, MA, United States., Sehgal V; Moderna, Inc., Cambridge, MA, United States., Chen X; Moderna, Inc., Cambridge, MA, United States., Morrissey M; Moderna, Inc., Cambridge, MA, United States., Daghestani HN; Moderna, Inc., Cambridge, MA, United States., Feldman I; Moderna, Inc., Cambridge, MA, United States., Srinivasan L; Moderna Therapeutics (United States), Cambridge, MA, United States., Frederick JP; Moderna Inc., Cambridge, MA, United States., Brown M; Moderna, Inc., Cambridge, MA, United States., Aanur P; Moderna, Inc., Cambridge, MA, United States., Meehan R; Moderna, Inc., Boston, MA, United States., Burris HA; Sarah Cannon Research Institute, Nashville, TN, United States.

المصدر: Cancer discovery [Cancer Discov] 2024 Aug 08. Date of Electronic Publication: 2024 Aug 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

المؤلفون: Saba NF; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Wong SJ; Department of Medicine, Medical College of Wisconsin, Pleasant Prairie., Nasti T; Winship Cancer Institute, Emory University, Atlanta, Georgia.; The Emory Vaccine Center, Emory University, Atlanta, Georgia., McCook-Veal AA; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia., McDonald MW; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Stokes WA; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Anderson AM; Winship Cancer Institute, Emory University, Atlanta, Georgia., Ekpenyong A; Winship Cancer Institute, Emory University, Atlanta, Georgia., Rupji M; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia., Abousaud M; Astellas Pharma Global Development Inc, Northbrook, Illinois., Rudra S; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Bates JE; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Remick JS; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Joshi NP; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Woody NM; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Awan M; Department of Medicine, Medical College of Wisconsin, Pleasant Prairie., Geiger JL; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Shreenivas A; Department of Medicine, Medical College of Wisconsin, Pleasant Prairie., Samsa J; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Ward MC; Radiation Therapy Center, Atrium Health Levine Cancer Institute, Charlotte, North Carolina., Schmitt NC; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Otolaryngology, Emory University, Atlanta, Georgia., Patel MR; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Otolaryngology, Emory University, Atlanta, Georgia., Higgins KA; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Teng Y; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Steuer CE; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Shin DM; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Liu Y; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia., Ahmed R; Winship Cancer Institute, Emory University, Atlanta, Georgia.; The Emory Vaccine Center, Emory University, Atlanta, Georgia., Koyfman SA; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio.

المصدر: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 896-904.

نوع المنشور: Journal Article; Multicenter Study; Clinical Trial, Phase II

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Nivolumab*/therapeutic use , Nivolumab*/adverse effects , Squamous Cell Carcinoma of Head and Neck*/radiotherapy , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/therapy , Squamous Cell Carcinoma of Head and Neck*/pathology , Squamous Cell Carcinoma of Head and Neck*/mortality , Radiotherapy, Intensity-Modulated*/methods , Radiotherapy, Intensity-Modulated*/adverse effects , Neoplasm Recurrence, Local*/radiotherapy , Head and Neck Neoplasms*/radiotherapy , Head and Neck Neoplasms*/pathology , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/therapy , Head and Neck Neoplasms*/mortality, Humans ; Male ; Female ; Middle Aged ; Aged ; Re-Irradiation/methods ; Re-Irradiation/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Neoplasms, Second Primary ; Progression-Free Survival ; Adult

المؤلفون: Yalamanchali A; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Griffith C; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA., Reddy CA; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Koyfman SA; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Woody NM; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Campbell SR; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Silver N; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Scharpf J; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Lorenz RR; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Prendes B; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Ku JA; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Lamarre E; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Geiger JL; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.

المصدر: Head & neck [Head Neck] 2024 Sep; Vol. 46 (9), pp. 2340-2347. Date of Electronic Publication: 2024 Apr 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley And Sons Country of Publication: United States NLM ID: 8902541 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0347 (Electronic) Linking ISSN: 10433074 NLM ISO Abbreviation: Head Neck Subsets: MEDLINE

مواضيع طبية MeSH: Mouth Neoplasms*/pathology , Mouth Neoplasms*/mortality , Mouth Neoplasms*/therapy , Mouth Neoplasms*/surgery , Carcinoma, Squamous Cell*/pathology , Carcinoma, Squamous Cell*/mortality , Carcinoma, Squamous Cell*/therapy , Carcinoma, Squamous Cell*/surgery , Extranodal Extension*/pathology, Humans ; Male ; Female ; Middle Aged ; Aged ; Disease-Free Survival ; Retrospective Studies ; Neoplasm Staging ; Proportional Hazards Models ; Adult ; Treatment Outcome